maximum weight loss tirzepatide surmount trials Full article: Tirzepatide for overweight and obesity management

In the SURMOUNT-4 trial, 82.5% of adults with obesity regained ≥25% of initial weight lost within one year of tirzepatide withdrawal; most showed reversal of cardiometabolic improvements. https://ja.ma/4qaMLfO

21.73

★★★★☆4.8 (126)

🔬 NEW: Tirzepatide maintains 21.9% weight loss after 2+ years of treatment. The SURMOUNT-MAINTAIN trial shows that continuing the medication at full dose is crucial for long-term obesity management. Stopping or reducing

22.92

★★★★★4.9 (98)

📉💉 What Is a Mounjaro Plateau & How Does Long-Term Use Affect Weight Loss Results? Many patients on Mounjaro (tirzepatide) experience rapid early weight loss but over time, progress can slow as

24.90

★★★★★5.0 (157)

Tirzepatide has transformed the treatment landscape for people living with obesity and for those with poorly controlled type 2 diabetes mellitus. Despite its established clinical benefits, the precise molecular and cellular mechanisms

26.72

★★★★★4.7 (84)

Adults with obesity using tirzepatide maintain 'remarkable' weight loss at 88 weeks

29.09

★★★★★4.9 (203)

Time to weight plateau with tirzepatide treatment in the SURMOUNT‐1 and SURMOUNT‐4 clinical trials - Horn - 2025 - Clinical Obesity

22.09

★★★★★5.0 (176)

Tirzepatide shows 47% greater weight loss vs. Wegovy

29.01

★★★★★4.8 (132)